EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease

Marie-Camille Lafargue, Mickaël Bobot, Helmut G Rennke, Marie Essig, Martin Carre, Lucile Mercadal, Jonathan Farhi, Hamza Sakhi, Thibault Comont, Léonard Golbin, Pierre Isnard, Jonathan Chemouny und 10 weitere

Kidney International Reports · 2023-12 · 8 (12) · 2733-2741

DOI: 10.1016/j.ekir.2023.09.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International Reports, 2023-12. Verfasst von Marie-Camille Lafargue und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Tenon's Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Chronic myelomonocytic leukemia (CMML) is a hematologic disorder that is an overlap syndrome between myelodysplastic syndromes and myeloproliferative neoplasms, and can be associated with autoimmune and inflammatory diseases. This study aimed to describe kidney involvement in patients with CMML, their treatments, and outcomes.

Methods

We conducted a French and American multicenter retrospective study in 15 centers, identifying patients with CMML with acute kidney injury (AKI), chronic kidney disease (CKD), and urine abnormalities.

Results

Sixteen patients (males, n = 14; median age 76.5 years [71.9-83]) developed a kidney disease 6 months [1.6-25.6] after the diagnosis of CMML. At the time of kidney disease diagnosis, median urinary protein-to-creatinine ratio was 2 g/g [1.25-3.4], and median serum creatinine was 2.26 mg/dl [1.46-2.68]. Fourteen patients (87.5%) underwent a kidney biopsy, and the 2 main pathological findings were lysozyme nephropathy (56%) and renal infiltration by the CMML (37.5%). Ten patients received a new treatment following the CMML-associated kidney injury. Among patients with monitored kidney function, and after a median follow-up of 15 months [9.9-34.9], 4 patients had CKD stage 3, 4 had CKD stage 4, 1 had an end-stage kidney disease. In our patient series, 2 patients evolved to an acute myeloid leukemia (AML), and 5 died. Compared with 116 CMML controls, patients who had a kidney involvement had a higher monocyte count (P < 0.001), had more CMML-1 (P = 0.005), were more susceptible to develop an AML (P = 0.02), and were more eligible to receive a specific hematologic treatment, with hydroxyurea, or hypomethylating agents (P < 0.001), but no survival difference was seen between the 2 groups (P = 0.6978).

Conclusion

In this cohort of patients with CMML with a kidney injury, the 2 most frequent renal complications were lysozyme-induced nephropathy and renal infiltration by the CMML. Kidney involvement should be closely monitored in patients with CMML.

Schlagwörter

Stichwörter der Autor:innen

acute kidney injurychronic myelomonocytic leukemia

Autor:innen und Institutionen

  • Department of Nephrology, Tenon's Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France.
  • Centre de Néphrologie et Transplantation Rénale, AP-HM, Hôpital de la Conception, CHU de la Conception, 13005, Marseille, France.
  • Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Nephrology, Assistance Publique-Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne-Billancourt, Université Paris-Saclay, Paris, France.
  • Service d'Hématologie, Centre Hospitalier Universitaire, Grenoble, France.
  • Department of Nephrology and Renal Transplantation, Assistance Publique-Hôpitaux de Paris, Hôpital de La Pitié Salpêtrière, Paris, France.

Zitieren

APA

Lafargue, M. C., Bobot, M., Rennke, H. G., Essig, M., Carre, M., Mercadal, L., Farhi, J., Sakhi, H., Comont, T., Golbin, L., Isnard, P., Chemouny, J., Cambier, N., Laribi, K., Selamet, U., Riella, L. V., Fain, O., Adès, L., Fenaux, P., …, & MINHEMON, GFM and French VEXAS group (2023). Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease. Kidney International Reports, 8(12), 2733-2741. https://doi.org/10.1016/j.ekir.2023.09.005

Vancouver

Lafargue MC, Bobot M, Rennke HG, Essig M, Carre M, Mercadal L, et al. Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease. Kidney International Reports. 2023;8(12):2733-2741. doi:10.1016/j.ekir.2023.09.005

BibTeX
@article{Lafargue2023,
  author = {Lafargue, Marie-Camille and Bobot, Mickaël and Rennke, Helmut G and Essig, Marie and Carre, Martin and Mercadal, Lucile and Farhi, Jonathan and Sakhi, Hamza and Comont, Thibault and Golbin, Léonard and Isnard, Pierre and Chemouny, Jonathan and Cambier, Nathalie and Laribi, Kamel and Selamet, Umut and Riella, Leonardo V and Fain, Olivier and Adès, Lionel and Fenaux, Pierre and Cohen, Camille and Mekinian, Arsène and MINHEMON, GFM and French VEXAS group, MINHEMON, GFM and French VEXAS group},
  title = {Chronic Myelomonocytic Leukemia Patients With Lysozyme Nephropathy and Renal Infiltration Display Markers of Severe Disease},
  journal = {Kidney International Reports},
  year = {2023},
  volume = {8},
  number = {12},
  pages = {2733--2741},
  doi = {10.1016/j.ekir.2023.09.005}
}
Kostenlos starten →